Program
HDM1005
A development code. Also written as “HDM1005 1”, “HDM1005 2” and “HDM1005 dose level 1”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Sleep Apnea, Obstructive · Overweight, led by Huadong Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huadong Medicine | 1010 open or running | phase 3since Nov 17, 2025 | Jul 25, 2025 | Dec 1, 2026phase 1 · NCT07502001 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 25, 2025First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT07109700 · 216 planned · China
- Nov 17, 2025Phase 3 study in ObesityPhase 3 reachedNCT07279194 · 825 planned · China
- Feb 2, 20262 phase 3 studies in Diabetes Mellitus, Type 2NCT07394114, NCT07417306
- Mar 19, 2026Phase 1 study in OverweightNCT07502001 · 42 planned · China
- Mar 31, 2026Phase 2 study in ObesityNCT07521631 · 372 planned · China
- Apr 23, 2026Phase 1 study in OverweightNCT07559240 · 30 planned · China
- Aug 24, 20262 phase 3 studies in Sleep Apnea, ObstructiveNCT07787260, NCT07794397
- Sep 14, 2026Phase 1 study in Overweight and/or ObesityNCT07828197 · 135 enrolled · China
Ahead
- Dec 1, 2026Primary completion: phase 1 study in OverweightNCT07502001
- Feb 4, 2027Primary completion: phase 2 study in ObesityNCT07521631
- Aug 28, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07394114
- Aug 30, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07417306
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07828197Overweight and/or Obesity · China | 1 | Active, not recruiting | Oct 2026 | 135 |
| NCT07794397Sleep Apnea, Obstructive · China | 3 | Not yet recruiting | Sep 2028 | 200 |
| NCT07787260Sleep Apnea, Obstructive · China | 3 | Not yet recruiting | Mar 2028 | 200 |
| NCT07559240Overweight · China | 1 | Not yet recruiting | Jun 12, 2026 | 30 |
| NCT07521631Obesity · China | 2 | Recruiting | Feb 4, 2027 | 372 |
| NCT07502001Overweight · China | 1 | Not yet recruiting | Dec 1, 2026 | 42 |
| NCT07417306Diabetes Mellitus, Type 2 · China | 3 | Not yet recruiting | Aug 30, 2027 | 912 |
| NCT07394114Diabetes Mellitus, Type 2 · China | 3 | Recruiting | Aug 28, 2027 | 240 |
| NCT07279194Obesity · China | 3 | Recruiting | Sep 20, 2026 | 825 |
| NCT07109700Diabetes Mellitus, Type 2 · China | 2 | Recruiting | Jan 31, 2026 | 216 |
How it is read
Names in the registry
- “HDM1005”, 4 entries
- “HDM1005 1”, 4 entries
- “HDM1005 2”, 4 entries
- “HDM1005 dose level 1”, 1 entry
- “HDM1005 dose level 2”, 1 entry
Codes read as this program: HDM1005.
Conditions, from the studies’ own filings
- Obesity, 4 studies
- Diabetes Mellitus, Type 2, 3 studies
- Sleep Apnea, Obstructive, 2 studies
- Overweight, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.